全文获取类型
收费全文 | 236篇 |
免费 | 5篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 8篇 |
妇产科学 | 5篇 |
基础医学 | 32篇 |
口腔科学 | 2篇 |
临床医学 | 63篇 |
内科学 | 43篇 |
皮肤病学 | 2篇 |
神经病学 | 3篇 |
特种医学 | 11篇 |
外科学 | 24篇 |
综合类 | 4篇 |
预防医学 | 14篇 |
眼科学 | 2篇 |
药学 | 18篇 |
肿瘤学 | 5篇 |
出版年
2021年 | 4篇 |
2020年 | 3篇 |
2018年 | 3篇 |
2017年 | 3篇 |
2016年 | 2篇 |
2015年 | 3篇 |
2014年 | 4篇 |
2012年 | 2篇 |
2011年 | 10篇 |
2010年 | 3篇 |
2008年 | 7篇 |
2007年 | 8篇 |
2006年 | 11篇 |
2005年 | 4篇 |
2004年 | 11篇 |
2003年 | 5篇 |
2002年 | 5篇 |
2001年 | 3篇 |
2000年 | 5篇 |
1999年 | 7篇 |
1998年 | 7篇 |
1997年 | 4篇 |
1995年 | 3篇 |
1994年 | 3篇 |
1993年 | 2篇 |
1992年 | 5篇 |
1991年 | 7篇 |
1990年 | 7篇 |
1989年 | 10篇 |
1988年 | 9篇 |
1987年 | 11篇 |
1986年 | 5篇 |
1985年 | 3篇 |
1983年 | 3篇 |
1982年 | 1篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1979年 | 4篇 |
1978年 | 5篇 |
1977年 | 4篇 |
1976年 | 3篇 |
1975年 | 5篇 |
1974年 | 6篇 |
1973年 | 3篇 |
1972年 | 1篇 |
1971年 | 3篇 |
1970年 | 7篇 |
1969年 | 4篇 |
1968年 | 3篇 |
1966年 | 6篇 |
排序方式: 共有241条查询结果,搜索用时 46 毫秒
1.
2.
3.
4.
5.
6.
Alex M. Hollenberg Noorullah Maqsoodi Amy Phan Aric Huber Ayodeji Jubril Avionna L. Baldwin Noriaki Yokogawa Roman A. Eliseev Addisu Mesfin 《The spine journal》2021,21(7):1205-1216
BACKGROUND CONTEXTBack and neck pain secondary to disc degeneration is a major public health burden. There is a need for therapeutic treatments to restore intervertebral disc (IVD) composition and function.PURPOSETo quantify ALK3, BMP-2, pSMAD1/5/8 and MMP-13 expression in IVD specimens collected from patients undergoing surgery for disc degeneration, to correlate ALK3, BMP-2, pSMAD1/5/8 and MMP-13 expression in IVD specimens to the 5-level Pfirrmann MRI grading system, and to compare ALK3, BMP-2, pSMAD1/5/8 and MMP-13 expression between cervical and lumbar degenerative disc specimens.STUDY DESIGNAn immunohistochemical study assessing ALK3, BMP-2, pSMAD1/5/8, and MMP-13 expression levels in human control and degenerative IVD specimens.METHODSHuman IVD specimens were collected from surgical patients who underwent discectomy and interbody fusion at our institution between 1/2015 and 8/2017. Each patient underwent MRI prior to surgery. The degree of disc degeneration was measured according to the 5-level Pfirrmann MRI grading system. Patients were categorized into either the 1) control group (Pfirrmann grades I-II) or 2) degenerative group (Pfirrmann grades III-V). Histology slides of the collected IVD specimens were prepared and immunohistochemical staining was performed to assess ALK3, BMP-2, pSMAD1/5/8, and MMP-13 expression levels in the control and degenerative specimens. Expression levels were also correlated to the Pfirrmann criteria. Lastly, the degenerative specimens were stratified according to their vertebral level and expression levels between the degenerative lumbar and cervical discs were compared.RESULTSFifty-two patients were enrolled; however, 2 control and 2 degenerative patients were excluded due to incomplete data sets. Of the remaining 48 patients, there were 12 control and 36 degenerative specimens. Degenerative specimens had increased expression levels of BMP-2 (p=.0006) and pSMAD1/5/8 (p<.0001). Pfirrmann grade 3 (p=.0365) and grade 4 (p=.0008) discs had significantly higher BMP-2 expression as compared to grade 2 discs. Pfirrmann grade 4 discs had higher pSMAD1/5/8 expression as compared to grade 2 discs (p<.0001). There were no differences in ALK3 or MMP-13 expression between the control and degenerative discs (p>.05). Stratifying the degenerative specimens according to their vertebral level showed no significant differences in expression levels between the lumbar and cervical discs (p>.05).CONCLUSIONSBMP-2 and pSMAD1/5/8 signaling activity was significantly upregulated in the human degenerative specimens, while ALK3 and MMP-13 expression were not significantly changed. The expression levels of BMP-2 and pSMAD1/5/8 correlate positively with the degree of disc degeneration measured according to the Pfirrmann MRI grading system.CLINICAL SIGNIFICANCEBMP-SMAD signaling represents a promising therapeutic target to restore IVD composition and function in the setting of disc degeneration. 相似文献
7.
One-Year Follow-up of Duodenal Ulcers after 1-Wk Triple Therapy for Helicobacter pylori 总被引:1,自引:0,他引:1
Joseph J. Y. Sung M.D. S.C. Sydney Chung M.D. Thomas K. VV. Ling Ph.D. Man Yee Yung R.N. Augustin F. B. Cheng M.D. Shorland W. Hosking M.D. Arthur K. C. Li M.D. 《The American journal of gastroenterology》1994,89(2):199-202
Objective : to study the ulcer recurrence rate of Helicobacter pylori-positive duodenal ulcers at 1 yr after eradication of the bacteria by triple therapy. Method : Patients with H. pylori-positive duodenal ulcers were randomized to receive either triple therapy for 1 wk plus omeprazole for 4 wk (THple+OMP) (n = 78), or omeprazole alone (OMP) for 4 wk (N = 77). Patients were followed up every 3 months for symptom enquiry. At 1 yr, all asymptomatic patients were invited to attend for gastroscopy. Results : At 8 wk, 16 patients in the OMP group and four in the Triple+OMP group had an ulcer. During the 1-yr period, 12 patients in the OMP group and no patient in the Triple+OMP group developed symptomatic ulcers. At follow-up endoscopy at 1 yr, another 10 ulcers were detected in the OMP group and two in the Triple+OMP group. Fifteen patients in the OMP group and 13 in the Triple+OMP group were lost to follow-up. In total, ulcers were de-tected in 39 of 61 (64%) assessahle patients in the OMP group, and in six of 65 (97o) assessahle patients in the Triple+OMP group after I yr (χ2 test: p < 0.001). Of the patients whose H, pytori were successfully eradicated hy Triple+OMP at 8 wk, 90% remained H. pylori negative at 1 yr. Conclusion : Triple therapy for 1 wk eradicates H, pylori infection and significantly reduces duodenal ulcer relapses. 相似文献
8.
9.
H Havanka-Kanniainen E Hokkanen VV Myllylä 《Cephalalgia : an international journal of headache》1985,5(1):39-43
The efficacy of nimodipine in the prophylaxis of migraine was assessed in a double-blind, placebo-controlled, cross-over study carried out on 33 patients, 20 of whom suffered from classic and 13 from common migraine. Four patients dropped out, but not as a result of the side effects of the drug. The duration of drug treatment was 8 weeks. The dosage used was 30 mg four times daily. Nimodipine proved to be better than placebo, the number of migraine attacks and severity of headache showing a significant reduction. The drug was well tolerated and no marked side effects were noted. The results suggest that nimodipine is a useful new prophylactic drug for migraine, but further studies are needed before its final value can be evaluated. 相似文献
10.